Document:

Exhibit 10.21

 

MEDICINE MAN TECHNOLOGIES, INC.

 

December 16, 2020

 

 

Dye Capital Cann Holdings II, LLC

 

 

Ladies and Gentlemen:

 

 

This letter agreement
(this “Agreement”) will confirm our agreement that as a condition to your entering into the Purchase Agreement
(defined below) and pursuant to and effective upon the closing of your purchase (the “Purchase”) of up to 13,000
shares of Series A Preferred Stock of Medicine Man Technologies, Inc. (the “Company”), Dye Capital Cann Holdings
II, LLC (the “Investor”) shall be entitled to the contractual rights set forth below, in addition to the rights
specifically set forth in the Securities Purchase Agreement dated November 16, 2020 by and among the Company and the investors
that are party thereto, as amended by the Amendment to the Securities Purchase Agreement dated the date hereof (the “Purchase
Agreement”) and the Certificate of Designation of the Company that is attached as Exhibit A to the Purchase Agreement
(the “Certificate of Designation”). Capitalized terms that are used but not defined herein shall have the meaning
given to them in the Purchase Agreement or, if applicable, the Certificate of Designation.

 

		1.	Board Nomination Rights.

 

(a)           
The Company shall take all actions to ensure that from and after the Closing Date and for so long as the Investor meets the
Ownership Threshold (as defined below), one individual designated by the Investor shall be appointed to the board of
directors of the Company (the “Board”) if the Board consists of five or fewer members and two individuals
designated by the Investor shall be appointed to the Board if the Board consists of more than five members (each an
“Investor Designee”). For purposes hereof, “Ownership Threshold” means that the
Investor owns, in the aggregate, at least $10,000,000 of Preferred Stock, on an as-converted to Common Stock basis, as of any
date of determination, based on the 30-Day Trailing VWAP (as defined below); provided, however, that the Ownership Threshold
shall automatically be deemed to be satisfied at any time the Buyer holds at least 10,000 (as such amount may be adjusted for
stock splits, subdivisions, combinations and the like) shares of Preferred Stock. For purposes hereof,
“30-Day Trailing VWAP” means, as of any date of determination, the volume-weighted average price per share
of Common Stock on the exchange on which the Common Stock is then traded during the regular trading session (and excluding
pre-market and after-hours trading) over the thirty (30) consecutive trading days prior to and including such determination
date. The Investor’s initial Investor Designee shall be Pratap Muharji (the “Initial Designee”). On
or prior to the Closing Date, the Company shall take all actions necessary to cause the appointment to the Board of the
Initial Designee effective as of the Closing Date, and thereafter, for so long as the Investor’s Board nomination right
under this Section 1 continues, the Company will use its best efforts to ensure that each Investor Designee is elected to the
Board (including recommending that the Company’s stockholders vote in favor of the election of such designees,
soliciting proxies and contesting any proxy contest and otherwise supporting such designees for election in a manner no less
rigorous and favorable than the manner in which the Company supports its other nominees); provided that if the Investor
determines to designate a different individual (“Replacement Designee”) as an Investor Designee, such
obligation shall instead apply to such Replacement Designee. If an Investor Designee ceases to be a director of the Company,
the Company shall take all actions necessary to cause the appointment to the Board of a Replacement Designee nominated by the
Investor to fill the vacancy and thereafter the Company will use its best efforts to cause the election of such an individual
to the Board, subject to the same conditions and limitations as set forth in the foregoing sentence. Each Investor Designee
shall be entitled to the level of compensation, directors’ and officers’ indemnity insurance coverage and
indemnity and exculpation protection (including under any indemnification agreement) as the other members of the Board in
their capacities as directors. Each Investor Designee shall be entitled to the same level of directors’ and
officers’ indemnity insurance coverage and indemnity and exculpation protection (including under any indemnification
agreement) as the other members of the Board. As promptly as practicable, and for so long as an Investor Designee serves on
the Company’s board of directors, the Company shall maintain in place directors’ and officers’ indemnity
insurance coverage in an amount and on terms deemed reasonably acceptable to the Investor Designees, but no less than $2
million of coverage per director.

 

 

 

    	 	1	 

     

    

 

(b)           
For so long as the Investor is entitled to designate Investor Designees for election to the Board under this letter agreement,
each committee of the Board shall include at least one Investor Designee as a member or, if the Investor so elects, as an observer;
provided, however, that if such Investor Designee is not eligible for membership on any given committee of the Board under then
applicable listing and corporate governance standards of a trading exchange or any Applicable Law, then such committee shall include
such Investor Designee as an observer only; provided, further, that the Company shall exercise all authority under Applicable
Law to permit the inclusion of such Investor Designee on such committee, including, without limitation, by causing an increase
in the number of directors on such committee.

 

(c)           
Any Investor Designee shall take all action reasonably requested by the Company, at the Company’s cost and expense, to comply
with applicable state cannabis laws and regulations, including, without limitation, making all requisite filings under such laws
and regulations as and when requested by the Company and the Investor Designee shall, at the Company’s cost and expense,
reasonably cooperate with the Company with respect to any report, filing, notification or other communication with or to any state
governmental authority related to the Company’s licenses, approvals, consents or obligations under state cannabis laws and
regulations related to such Investor Designee’s capacity as director of the Company, including, without limitation, any investigation
or inquiry by a state governmental authority related to any of the foregoing. If an Investor Designee is determined to be unsuitable
or disqualified to serve on the Board by a state governmental authority, including, without limitation, the Colorado Marijuana
Enforcement Division, such Investor Designee shall immediately resign from the Board and the Investor shall be entitled to appoint
a Replacement Designee in accordance with the provisions of Section 1(a) above.

 

2.             
This Agreement and the rights, privileges and obligations herein are personal to the Investor and may not be assigned, transferred,
subcontracted or delegated (in whole or in part) by the Investor, including by operation of law, without the prior written consent
of the Company.

 

3.             
Unless earlier terminated pursuant to the terms hereof, this Agreement and the rights described herein, other than the last three
sentences of Section 1(a) above and Sections 2 through 4, shall terminate and be of no further force or effect upon the earlier
of: (a) a Listing Event; or (b) a Change of Control Transaction.

 

4.             
The parties acknowledge and agree that this Agreement is a Transaction Document as such term is defined under the Purchase Agreement.

 

[Signature Page Follows]

 

 

 

 

 

 

 

 

 

 

 

 

 

    	 	2	 

     

    

 

 

Very truly yours,

 

MEDICINE MAN TECHNOLOGIES,
INC.

 

By: /s/ Nancy Huber                                    

 

Name: Nancy Huber

 

Title: Chief Financial Officer

 

 

 

 

 

 

	 	Accepted and agreed:
	 	 
	 	 
	 	DYE CAPITAL CANN HOLDINGS II, LLC
	 	 
	 	By: Dye Capital & Company,
        LLC,
	 	its Managing Member
	 	 
	 	 
	 	 
	 	By:   Justin Dye                                    
	 	Name: Justin Dye
	 	Title: Authorized Person

 

 

 

 

 

 

 

 

 

 

    	 	3Exhibit 10.24

 

 

	 	Paul D. Dickman	 
	 	33680 County
Rd. 112,	 
	 	Robertsdale
, AL 36567	March 20, 2020
	 	 	 
	 	 	 
	 	Dear Mr. Dickman,	 

 

 

It has
come to our attention that Medicine Man Technologies, Inc. erroneously issued 500,000 shares of common stock to you on or about
January 8, 2019. The grant of such 500,000 shares of common stock is explicitly contingent upon the common stock meeting certain
milestones within 36 months from the date of the board of directors' approval -(i) market price of $8.00 per share and (ii)
minimum of250,000 shares in average daily trading volume for five consecutive trading days. The shares should not have been issued
until the conditions are met. Therefore, we have instructed our common stock transfer agent to cancel the stock certificate representing
these shares. In connection with the cancellation of these shares, we hereby request that you (i) countersign this letter and
(ii) return this countersigned letter and stock certificates number
1880 and 1881 to us by putting it in the pre-paid UPS envelope enclosed herewith and sending it back to us.

 

We
are requesting the original stock certificates for everyone's protection,
in order to prevent the possibility that someone may innocently believe that the stock certificates represents validly issued shares
of Medicine Man Technologies, Inc. Failure to promptly return the stock certificate could result in us taking action against you,
including but not limited to, termination

of the Consulting Agreement for
Cause.

 

At such time as the
milestones described above are met, the Company will issue a new stock certificate to you representing the shares.

 

Thank you for your cooperation.

 

Sincerely,

 

 

	 	/s/ Daniel R. Pabon	 
	 	Daniel R. Pabon	 
	 	General Counsel	/s/ Paul Dickman                        3/23/2020
	 	Medicine Man Technologies, Inc.	Paul D. Dickman                         Date
	 	 	 
	 	 	 

 

 

 

 

 

 

 

 

4880 Havana St., Suite 201, Denver,
CO 80239

 

 

 

    	 	1	 

     

    

    	 	2	 

     

    

    	 	3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]